Carl Zeiss Meditec Aktie

Carl Zeiss Meditec für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 531370 / ISIN: DE0005313704

<
Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Orderbuch
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
17.06.2024 10:09:39

EQS-Adhoc: Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Change in Forecast/Profit Warning
Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business

17-Jun-2024 / 10:09 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
 
Jena, June 17, 2024
In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313704) had preliminary revenue of € 1,258 million (prior year: € 1,297 million, -3%). Preliminary operating profit (EBIT) amounted to € 135 million (prior year: € 183 million, -26%), excluding the contribution from the acquisition of DORC as well as integration cost related to the acquisition. In the combined months of April and May 2024, order entry, revenue and EBIT continued to fall short of the previous year’s level. As a consequence of the continued slow business development, the previous forecast for FY 2023/24 is lowered: Revenue is now expected to reach around € 2,000 million, excluding the contribution from the acquisition of DORC, which continues to be estimated at an additional € 100 million for the second half of the fiscal year (previous target: € 2,100 - € 2,150 million, excluding DORC). Due mainly to the resulting lack of positive operating leverage from weaker overall revenue assumptions, as well as more cautious assumptions for consumables sales in the second half of the current fiscal year, leading to a weaker product mix, EBIT (excluding effects related to the DORC acquisition) will fall significantly short of the previously stated target of a comparable level to last year (€ 348.1 million) and reach a level between around € 215 million up to around € 265 million.

Soft development of order entry and revenue continues to be mainly driven by the equipment business, suffering from a restrictive investment climate among key customer groups, particularly in North America. In addition, the important peak season for refractive surgeries in China is off to a slow start, with consumables orders in the country trailing the past year’s figures during the third quarter so far. The slower than anticipated roll-out of national volume-based procurement for intraocular lenses in China is also causing an additional headwind to revenue and EBIT.

Management is taking further measures to reduce operating expenses to adjust to the weaker market environment, predominantly in sales & marketing as well as research & development. A further update will be provided with Q3 2023/24 results on August 6, 2024.

Carl Zeiss Meditec is targeting renewed growth for the upcoming fiscal year 2024/25, supported by the launch of innovative new products into key markets in both strategic business units. In the mid-term, the goals of growing at least as fast as the underlying markets as well as reaching an EBIT margin level sustainably above 20% remain unchanged.

The quarterly statement for 9M 2023/24 will be published on August 6, 2024.
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.meditec@zeiss.com

 

 

 

 

 

 

 

 

 



End of Inside Information

17-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1926437

 
End of Announcement EQS News Service

1926437  17-Jun-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1926437&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!

Nachrichten zu Carl Zeiss Meditec AGmehr Nachrichten

Analysen zu Carl Zeiss Meditec AGmehr Analysen

26.11.25 Carl Zeiss Meditec Sector Perform RBC Capital Markets
24.11.25 Carl Zeiss Meditec Overweight Barclays Capital
28.10.25 Carl Zeiss Meditec Underweight JP Morgan Chase & Co.
24.10.25 Carl Zeiss Meditec Hold Deutsche Bank AG
20.10.25 Carl Zeiss Meditec Outperform Bernstein Research
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Newssuche

GO

Aktien in diesem Artikel

Carl Zeiss Meditec AG 44,52 -0,04% Carl Zeiss Meditec AG

Letzte Top-Ranking Nachrichten

03:15 Bitcoin, Ether & Co. im November 2025: Monatsbilanz der Kryptowährungen
03:10 November 2025: Die Tops und Flops unter den Rohstoffen im abgelaufenen Monat
30.11.25 KW 48: So performten die DAX-Aktien in der vergangenen Woche
30.11.25 Gold, Öl & Co. in KW 48: Die Tops und Flops unter den Rohstoffen
30.11.25 Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 48

Börse aktuell - Live Ticker

ATX und DAX gehen etwas höher ins Wochenende -- US-Börsen beenden "Black Friday"-Handel im Plus -- Asiens Börsen schließen uneins
Der heimische Markt zeigte sich am Freitag etwas fester. Der deutsche Leitindex präsentierte sich vor dem Wochenende mit leichten Gewinnen. Auch die US-Börsen legten zu. Die Märkte in Fernost bewegten sich am Freitag in unterschiedliche Richtungen.
Aktien ATX  DAX  EuroStoxx 50  Dow Jones  NASDAQ 100  Nikkei 225  S&P 500 

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen